Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient Perspective on the Management of Cancer Pain in Spain.
García-Foncillas J, Antón-Torres A, Caballero-Martínez F, Campos FJ, Feyjoo M, de Liaño AG, Monge D, Camps C. García-Foncillas J, et al. J Patient Exp. 2020 Dec;7(6):1417-1424. doi: 10.1177/2374373520978872. Epub 2021 Jan 3. J Patient Exp. 2020. PMID: 33457596 Free PMC article.
5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Cervantes A, Villar-Grimalt A, Abad A, Antón-Torres A, Belón J, Dorta J, Tres A, Camps C, Fonseca E, Massutí B, et al. Cervantes A, et al. Ann Oncol. 1993 Nov;4(9):753-7. doi: 10.1093/oxfordjournals.annonc.a058660. Ann Oncol. 1993. PMID: 8280656 Free article. Clinical Trial.
A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer.
Díaz-Rubio García E, Abad Esteve A, Antón Torres A, Aranda Aguilar E, Benavides Orgaz M, Carrato Mena A, Cervantes Ruipérez A, Feliu Batle J, García Alfonso P, García Foncillas J, Grávalos Castro C, Navarro García M, Rivera Herrero F, Tabernero Caturla JM. Díaz-Rubio García E, et al. Clin Transl Oncol. 2005 Jan-Feb;7(1):3-11. doi: 10.1007/BF02710019. Clin Transl Oncol. 2005. PMID: 15890149 Review.
Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study.
López López R, Camps Herrero C, Khosravi-Shahi P, Guillem Porta V, Carrato Mena A, Garcia-Foncillas J, Cruz Hernández JJ, Gascón Vilaplana P, Antón Torres A, Diaz-Rubio E, Feyjoo Saus M, Aranda Aguilar E. López López R, et al. Clin Transl Oncol. 2018 May;20(5):613-618. doi: 10.1007/s12094-017-1756-5. Epub 2017 Oct 3. Clin Transl Oncol. 2018. PMID: 28975575
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.
Camps-Herrero C, Paz-Ares L, Codes M, López-López R, Antón-Torres A, Gascón-Vilaplana P, Guillem-Porta V, Carrato A, Cruz-Hernández JJ, Caballero-Díaz C, Blasco-Cordellat A, Moreno-Nogueira JA, Díaz-Rubio E. Camps-Herrero C, et al. Clin Transl Oncol. 2014 Oct;16(10):914-20. doi: 10.1007/s12094-014-1170-1. Epub 2014 Jun 13. Clin Transl Oncol. 2014. PMID: 24924625
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Aranda E, Cervantes A, Carrato A, Fernández-Martos C, Antón-Torres A, Massutí T, Barneto I, García-Conde J, Barón JM, Díaz-Rubio E. Aranda E, et al. Ann Oncol. 1996 Aug;7(6):581-5. doi: 10.1093/oxfordjournals.annonc.a010674. Ann Oncol. 1996. PMID: 8879371 Free article. Clinical Trial.
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
Aranda E, Díaz-Rubio E, Cervantes A, Antón-Torres A, Carrato A, Massutí T, Tabernero JM, Sastre J, Trés A, Aparicio J, López-Vega JM, Barneto I, García-Conde J. Aranda E, et al. Ann Oncol. 1998 Jul;9(7):727-31. doi: 10.1023/a:1008282824860. Ann Oncol. 1998. PMID: 9739438 Free article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
31 results